A Study of RO5045337 in Patients With Solid Tumors

Completed · Phase 1

Conditions studied: Neoplasms

In brief

This open-label, randomized, cross-over study will evaluate the effect of food on the pharmacokinetics of single oral doses of RO5045337 in patients with solid tumors. The anticipated time on study treatment is 3 weeks.

Key facts

Study ID

NCT01164033

Run by

Hoffmann-La Roche

People needed

76

Starts

2010-08-01

Expected to finish

2013-05-01

Last updated by the study team

2016-11-02

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Adult patients, >/=18 years of age
• Histologically confirmed solid tumor
• Life expectancy of >/=12 weeks
• ECOG performance status of 0 or 1
• Adequate bone marrow, renal and hepatic function

You may not qualify if…

• Patients receiving any other investigational agent or therapy administered with the intention to treat their malignancy within 28 days prior to study start
• Patients with pre-existing gastro-intestinal disorder
• Patients with uncontrolled intercurrent illness

Where it is running

• Study site — Scottsdale, Arizona, United States
• Study site — Kansas City, Kansas, United States
• Study site — Kensignton, Maryland, United States
• Study site — Dallas, Texas, United States
• Study site — San Antonio, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.